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Abstract
ERBB4 encodes the tyrosine kinase receptor HER4, a critical regulator of normal cell function and neurodevelopmental
processes in the brain. One of the key ligands of HER4 is neureglin-1 (NRG1), and the HER4-NRG1 signalling pathway is
essential in neural crest cell migration, and neuronal differentiation. Pharmacological inactivation of HER4 has been shown
to hasten the progression of epileptogenesis in rodent models, and heterozygous ERBB4 null mice are shown to have
cognitive deficits and delayed motor development. Thus far there is only a single case report in the literature of a
heterozygous ERBB4 deletion in a patient with intellectual disability (ID). We identified nine subjects from five unrelated
families with chromosome 2q34 deletions, resulting in heterozygous intragenic loss of multiple exons of ERBB4, associated
with either non-syndromic ID or generalised epilepsy. In one family, the deletion segregated with ID in five affected
relatives. Overall, this case series further supports that haploinsufficiency of ERBB4 leads to non-syndromic intellectual
disability or epilepsy.
Introduction
Human ERBB4 is located on chromosome 2q34, has 28
exons, encodes at least five protein coding transcripts and is
highly constrained against loss-of-function variants, with a
pLI (probability of loss-of-function intolerance) score of 1
[1]. It encodes a tyrosine kinase receptor HER4, a crucial
regulator of cell function and neurodevelopmental processes
in the brain. A vital ligand of HER4 is neureglin-1 (NRG1),
and the HER4-NRG1 signalling pathway is critical in the
migration of neural crest cells, and neuronal and glial dif-
ferentiation [2]. HER4 is expressed in many adult and foetal
tissues, with high expression in the brain and heart [3, 4].
Kasnauskiene et al. described a 15-year-old male patient
with hyperactivity, intellectual disability (ID) and severe
speech delay with a de novo 958 kb 2q34 deletion resulting
in loss of exons 1–3 of ERBB4 (OMIM 600543) [5]. Backx
et al. reported a de novo balanced translocation t(2;6)(q34;
p25.3) in a girl with early onset myoclonic encephalopathy
and profound psychomotor delay [6]. The 2q34 breakpoint
was located between exons 1 and 2 of ERBB4, which was
proposed to be the major driver of the phenotype. Walsh
et al. described a 399 kb deletion of the distal region of
ERBB4 in a patient with schizophrenia, resulting in loss of
exons 20–28 [7]. Array comparative genomic hybridisation
(array-CGH) in a large cohort of patients with autism
spectrum disorder identified two patients with intronic
deletions of ERBB4 [8]. A meta-analysis by Feng et al.
identified an ERBB4 intronic single nucleotide polymorph-
ism, rs707284, in association with schizophrenia [odds
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ratio= 0.91, 95% CI: 0.83–0.99, P = 0.035] [9]. Takahashi
et al. identified heterozygous ERBB4 missense variants in
three separate families with amyotrophic lateral sclerosis
(ALS) [10]. Although ERBB4 variants have been implicated
in several neurological phenotypes, their significance has
not been proven conclusively.
Methods
Case ascertainment
Informed consent was obtained from the probands or
guardians of all investigated subjects. Family 1 was ascer-
tained at the Manchester Centre for Genomic Medicine.
Written consent was from obtained from Family 1
(Research Ethics Committee (REC) number 11/H1003/3).
Additional cases were ascertained through the DECIPHER
(Database of Chromosomal Imbalance and Phenotype in
Humans using Ensembl Resources) (accessed 9th February
2020) database, by interrogating for high-confidence dele-
tions exclusively affecting ERBB4 in individuals with no
other pathogenic or potentially pathogenic Copy number
variants (CNVs) [11]. Clinical phenotypes were collected
using a bespoke proforma. The logarithm of odds (LOD)




Microarray and fluorescent in situ hybridisation
High-resolution whole-genome array-CGH was performed
using DNA extracted from peripheral blood using the
Oxford Gene Technology Cytosure constitutional version 3
Array, to investigate Families 1, 2 and 5. For the assessment
of Family 3, array-CGH was carried out using the Blue-
Gnome 8x60k v2.0 ISCA platform. Test DNA was refer-
enced against same-sex control DNA and data was analysed
in BlueFuse Multi v4.1. The 180k Cytosure ISCA v2 array
was used to assess the proband in Family 4. Where required,
2q34 fluorescence in situ hybridisation (FISH) studies were




Patient I:1 was a 61-year-old male referred to the clinical
genetics service with ID. He demonstrated minor problems
in attention, mild linguistic difficulties and problems with
reading, writing, spelling and calculation. A detailed neu-
ropsychological assessment identified primary problems
with executive functioning, though his memory was rela-
tively good and there were no notable problems with
visuospatial functioning. He had six children, four of
whom have ID (Fig. 1A). His second child (Family 1,
Patient II:2 in Fig. 1A), was born at 38 weeks gestation
with a birth weight of 3.03 kg. There were no neonatal
concerns. She was reported to have speech delay and mild
motor delay. She sat by 7 months and walked by two and a
half years. She was diagnosed with moderate to severe
learning difficulties and attended a special educational
needs school. At the age of 24 years, she could understand
simple instructions and read short sentences. She required
help with most activities of daily living including show-
ering, toileting and dressing. Her behaviour was unpre-
dictable with irritability and aggressive outbursts. She has
one daughter, III:3, who had normal developmental mile-
stones at the age of 2 years. Patient II:3 was born at full
term by normal delivery, with a birth weight of 2.72 kg. He
had moderate speech delay. He sat by 7 months and walked
by 18 months. He attended a special school. At the age of
23, he was noted to have unpredictable behaviour with
episodes of aggression. Patient II:5 is the fourth child of
Patient 1-I. He spoke his first words by 3 years of age and
walked by 18 months. He attended a special educational
needs school. Patient II:6 was born at full term with a birth
weight of 3.17 kg. The pregnancy was complicated by
maternal jaundice. He was able to speak in sentences by 7
years of age and walked by 2 years of age. He was noted to
have severe behavioural problems and aggression. At the
age of 16 years, he was studying Foundation level maths at
College. All affected individuals including the proband
were non-dysmorphic with normal growth parameters and
a normal general and neurological examination. Individuals
II:1 and II:4 in this family attained developmental mile-
stones within normal limits, attended mainstream schools
and did not have ID.
An array-CGH in Patient I:1 identified a chromosome
2q34 deletion of 276.5 kilobases (kb) encompassing exon
1 (numbered as in NM_005235.3 and demarcated from
g.213403173_213403565 in GRCh 37) of ERBB4
(NC_000002.11:g.(213170347_213255794)_(213532234_
213581360)del) (DECIPHER ID: 271941). Further array-
CGH and fluorescent in situ hybridisation (FISH) studies
showed that the deletion was present in all affected indi-
viduals and absent in all unaffected individuals who were
tested (Fig. 1A). The LOD score for the association of the
deletion with the phenotype in this family was calculated as
1.81 (recombination factor (ϴ)= 0; the number of infor-
mative meiosis/individuals (N)= 6, and the number of
recombinants (R)= 0).
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ERBB4 exonic deletions identified from DECIPHER
We identified 12 additional deletions exclusively encom-
passing ERBB4 from DECIPHER (Table 1) (Fig. 1). Of
these, six deletions involved at least one exon of ERBB4
and six were exclusively intronic. Out of six exonic dele-
tions, two were shown to have occurred de novo, and one
was maternally inherited. We collected more phenotype
details in four of these families with exonic deletions




Patient II:1 (Fig. 1A) was the second child of healthy, non-
consanguineous parents of normal intellect. Pregnancy was
complicated by a urinary tract infection in the third
trimester. He was born at 41 weeks gestation by normal
delivery with a birth weight of 3.71 kg. He manifested
speech delay and required speech and language therapy
from the age of 3 years. He was able to speak in short
sentences by 4 years of age. He attended a mainstream
school with extra support; his school age was 1 year behind
his chronological age. At 11 years of age, he could speak in
short sentences and understand simple instructions. He had
some behavioural difficulties such as irritability and angry
outbursts. On examination, he had no significant dys-
morphic features. His head circumference was 54.2 cm
(25th centile), height 149 cm (50–75th centile) and
weight 40 kg (50–75th centile). Array-CGH in Patient II:1
identified a chromosome 2q34 deletion of 1.15Mb
encompassing exons 2–28 of ERBB4 (NC_000002.11:g.
(211787769_211901530)_(213054251_213106838)del).
FISH studies performed on blood samples from both par-
ents for the ERBB4 deletion indicated that this CNV arose




































































Exonic deleons in study 
Intronic deleons
Exonic deleons not in study 
Fig. 1 Pedigrees of families described in this paper and 2q34
deletions that exclusively involve ERBB4. A Pedigrees of Families
1–5. Shaded boxes depict subjects with intellectual disability or epi-
lepsy; NT indicates not tested. ERBB4+/+ indicates two wild-type
alleles; ERBB4+/− indicates the presence of heterozygous ERBB4
exonic deletion. B Ideogram of chromosome 2 depicting DECIPHER
deletions. Exonic deletions included in our study are illustrated with
red boxes with vertical lines; exonic deletions not included in our
study are orange boxes with hatched lines; and purely intronic dele-
tions are green boxes with diagonal lines.
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Family 3
Patient II-2 (Fig. 1A) was the second child of unrelated
parents. Her father was noted to have a history of learning
difficulties and dyslexia at school. The proband was born at
39+ 3 weeks gestation with a birth weight of 3.28 kgs, by
normal vaginal delivery. A heart murmur was detected after
delivery, but an echocardiogram at 3 weeks of age showed a
normal heart structure and no further cardiology follow-up
was arranged. She achieved head control by 6 months, sat
by 8 months and walked by 10 months. Her first words were
at 2 years of age and she could speak in sentences by 5
years of age. She attended a special educational needs
school and her behaviour was noted to be challenging with
frequent outbursts. She was prescribed methylphenidate for
attention deficit hyperactivity disorder. Examination aged 8
years showed a non-dysmorphic child with a head cir-
cumference of 49.5 cm (0.4th centile), height 130.5 cm
(75th centile) and weight 25.7 kg (50th centile). Array-CGH
detected a 276.58 kb deletion encompassing exon 1 of
ERBB4 (NC_000002.11:g.(213170326_213255865)_
(213532447-213581503)del) which was not present in her
mother. Her father was not tested.
Family 4
Patient I:1 (Fig. 1A) presented at the age of 14 years with
generalised seizures. Following treatment with carbamaze-
pine for 2 years, he subsequently remained seizure-free for
20 years. He later presented at the age of 36 with tonic
clonic and absence seizures. His electroencephalogram
showed generalised epileptic discharges, and his MRI brain
scan showed no significant abnormalities. He was pre-
scribed levetiracetam and lamotrigine and had not had
further seizures on medication. There was no history of
developmental delay or ID. His clinical examination and
growth parameters were normal. He has one son who had a
history of febrile convulsions. A 313 kb deletion was
identified for Patient I:1 at chromosome 2q34 by array-
CGH encompassing exon 2 of ERBB4 (NC_000002.11:g.
(212812342_212973847)_(213286482-213403172)del). No
other family members were tested for this CNV.
Family 5
Patient I:1 (Fig. 1A) was the first child of unrelated parents
of normal intellect. Following an uncomplicated pregnancy,
he was born at 41+ 6 weeks gestation by vaginal delivery
with a birth weight of 3.29 kg. His gross motor milestones
were normal, and he walked by 12 months of age. He had
two words by the age of 2 years and eight words by the age
of 3 years. He was noted to have poor eye contact and
repetitive behaviour. At the age of 3 years and 10 months,
he could join two words together, wave goodbye, had a
palmar grip, and communicated using PECS (Picture
Exchange Communication System) and Makaton. He had
mild tooth crowding and pes planus. His head cir-
cumference was 51.2 cm (26th centile), height 101.8 cm
(53rd centile) and weight 17.7 kg (76th centile). Array-CGH
identified a chromosome 2q34 deletion of 162 kb encom-
passing exon 2 of ERBB4 (NC_000002.11:g.(212885516_
212945237)_(213106838_213170347)del). Testing for the
Fragile X syndrome (OMIM 300624) did not identify
FMR1 expansion. The deletion was found to be inherited
from unaffected mother.
Intronic ERBB4 deletions
From the six deletions from DECIPHER that were restricted
to intronic regions, five cases were shown to be inherited,
and in at least three instances the carrier parent was reported
to be phenotypically normal. The deletion was not proven to
have occurred de novo in any of the cases. The phenotype
of the patients with intronic ERBB4 deletions included
developmental delay, ID, pulmonary stenosis, facial
abnormality, polycystic kidney dysplasia and postaxial
polydactyly.
Discussion
Thus far, only one patient with ID and behavioural deficit
with an intragenic ERBB4 deletion has been reported [5].
Myoclonic encephalopathy, together with psychomotor
delay, has been described in another subject with a trans-
location resulting in disruption of ERBB4 [6]. Here, we
present the largest case series of individuals with chromo-
some 2q34 deletions that exclusively affect ERBB4. Several
observations point towards pathogenicity of the deletions
involving exons of ERBB4 in autosomal dominant ID or
epilepsy. Firstly, although all individuals were ascertained
on the basis of their genotype, all had developmental delay
or epilepsy (Table 1). Secondly, the deletion in Family
1 segregated with the phenotype and in Family 2, the
deletion was shown to have arisen de novo (Fig. 1A).
ERBB4 is integral to developmental processes, demon-
strated by HER4 knockout mice that die mid-
embryogenesis due to cardiac malformation [12]. Notably,
heterozygous null mice show delayed motor development,
memory deficits and altered cue use in Morris maze learning
[13]. Recovery knockout rodent models that lack HER4
brain expression have a reduced number of interneurons in
the brain and cortex that is not rescued after restoring HER4
expression in adults. These rodents manifest behavioural
deficits such as hyperactivity, impaired social interaction
and contextual fear memory [14]. The study of ERBB4
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function in rodent models suggests that almost all cells
expressing HER4 modify the effects of gamma-
Aminobutyric acid (GABA) in the cortex, hippocampus
and basal ganglia [15]. HER4 clusters and associates with
GABA receptors leading to receptor internalisation, indi-
cating its role in regulation of the interneuron network and
migration of GABA neurons, the dysfunction of which may
lead to a reduced number or function of cortical GABAergic
neurons [10, 16]. Tan et al. demonstrated acceleration in the
progression of kindling-induced epileptogenesis in mouse
models after HER4 inactivation or ERBB4 deletion [17].
In addition to ID and epilepsy, the patients in our series
demonstrated clinical features such as executive function-
ing difficulties, attention problems, linguistic difficulties,
moderate speech delay, mild motor delay, irritability,
aggressive outbursts, hyperactivity, and repetitive beha-
viour. We note that the affected individuals from Families 1
and 3 with similar deletions encompassing exon 1 of
ERBB4 share moderate speech delay, moderate ID and
behavioural difficulties in common. Families 4 and 5 share
deletions that include the Receptor L domain, with dis-
tinctive clinical features. Accordingly; there does not
appear to be a clear correlation between the severity of ID/
epilepsy or the presence of additional clinical features, and
the size or location of deletion. The reason why some
exonic deletions result in ID whereas others may cause
epilepsy is not clear. Aetiological overlap between ID and
epilepsy is well known and could potential explain the
phenotypic differences across patients, as evidenced by
dominant pathogenic variants in HECW2 and GRIN2B
[18, 19]. Intriguingly, the deletion of exons 20–28 in a
patient with schizophrenia reported by Walsh et al. was
shown to result in an alternative transcript deficient of the
intracellular kinase domain [7]. They proposed that the
alternative transcript could cause a dominant negative
effect and thus disrupt neuronal migration and synaptic
neurotransmission. In vitro functional studies of ALS-
causing mutant ERBB4 have been shown to result in
reduced autophosphorylation of HER4 after stimulation
with NRG1 [10]. Patient II:1 of Family 2 exhibited a large
deletion of exons 2-28 encompassing both the Receptor L
(ligand-binding) domains and tyrosine kinase domain of
ERBB4; with a distinct phenotype to that reported by
Walsh et al. Although haploinsufficiency appears to be the
most likely basis of the cases presented here, we cannot
exclude other mechanisms without functional studies.
Interestingly, the ERBB4 deletion in Family 5 was found
to be maternally inherited, though maternal intellect in I:2
was reportedly normal. It is possible that reduced pene-
trance and variable expressivity associated with ERBB4
haploinsufficiency could be explained by differences in the
genetic background or in the levels of expression of the
remaining allele. Further investigation and functional work
incorporating additional patients with ERBB4 variants is
required to fully ascertain their consequence on protein
function and resulting phenotype.
We propose that deletions that exclusively affect the
intronic regions of ERBB4 are less likely to be pathogenic.
This is based on the following observations—individuals
with the intronic deletions did not display consistent phe-
notypes, and intronic deletions were inherited from unaf-
fected parents in several patients (Table 1) (Fig. 1).
Furthermore, several other ERBB4 intronic deletions are
seen in control populations on the Database of Genomic
Variants (DGV) and these observations are similar to what
is observed with NRXN1 exonic and intronic deletions
[20, 21].
In summary, we demonstrate that 2q34 deletions that
result in loss of exons of ERBB4 may cause autosomal
dominant mild to moderate developmental delay, ID or
epilepsy. CNVs can help to identify novel disease-genes
[22–24]. This study, therefore, adds ERBB4 as a likely new
candidate gene for ID. Future work will be required to
identify if point variants in ERBB4 also cause ID.
Acknowledgements This study makes use of data generated by the
DECIPHER community. A full list of centres who contributed to the
generation of the data is available from http://decipher.sanger.ac.uk
and via email from decipher@sanger.ac.uk. One of the/The author(s)
of this publication are (a) member(s) of the European Reference
Network on Rare Congenital Malformations and Rare Intellectual
Disability ERN-ITHACA [EU Framework Partnership Agreement ID:
3HP-HP-FPA ERN-01-2016/739516].
Compliance with ethical standards
Conflict of interest The authors declare that they have no conflict of
interest.
Publisher’s note Springer Nature remains neutral with regard to
jurisdictional claims in published maps and institutional affiliations.
Open Access This article is licensed under a Creative Commons
Attribution 4.0 International License, which permits use, sharing,
adaptation, distribution and reproduction in any medium or format, as
long as you give appropriate credit to the original author(s) and the
source, provide a link to the Creative Commons license, and indicate if
changes were made. The images or other third party material in this
article are included in the article’s Creative Commons license, unless
indicated otherwise in a credit line to the material. If material is not
included in the article’s Creative Commons license and your intended
use is not permitted by statutory regulation or exceeds the permitted
use, you will need to obtain permission directly from the copyright
holder. To view a copy of this license, visit http://creativecommons.
org/licenses/by/4.0/.
References
1. Karczewski KJ, Francioli LC, Tiao G, Cummings BB, Alföldi J,
Wang Q, et al. The mutational constraint spectrum quantified from
variation in 141,456 humans. Nature. 2020;581:434–43.
Z. Hyder et al.
2. Law AJ, Kleinman JE, Weinberger DR, Weickert CS. Disease-
associated intronic variants in the ErbB4 gene are related to
altered ErbB4 splice-variant expression in the brain in schizo-
phrenia. Hum Mol Genet. 2007;16:129–41.
3. Srinivasan R, Poulsom R, Hurst HC, Gullick WJ. Expression of
the c-erbB-4/HER4 protein and mRNA in normal human fetal and
adult tissues and in a survey of nine solid tumour types. J Pathol.
1998;185:236–45.
4. Mechawar N, Lacoste B, Yu W-F, Srivastava LK, Quirion R.
Developmental profile of neuregulin receptor ErbB4 in postnatal
rat cerebral cortex and hippocampus. Neuroscience.
2007;148:126–39.
5. Kasnauskiene J, Ciuladaite Z, Preiksaitiene E, Utkus A, Peciulyte
A, Kučinskas V. A new single gene deletion on 2q34: ERBB4 is
associated with intellectual disability. Am J Med Genet.
2013;161:1487–90.
6. Backx L, Ceulemans B, Vermeesch JR, Devriendt K, Van, Esch
H. Early myoclonic encephalopathy caused by a disruption of the
neuregulin-1 receptor ErbB4. Eur J Hum Genet. 2009;17:378–82.
7. Walsh T, McClellan JM, McCarthy SE, Addington AM, Pierce
SB, Cooper GM, et al. Rare Structural Variants Disrupt Multiple
Genes in Neurodevelopmental Pathways in Schizophrenia. Sci-
ence. 2008;320:6.
8. Prasad A, Merico D, Thiruvahindrapuram B, Wei J, Lionel AC,
Sato D, et al. A discovery resource of rare copy number variations
in individuals with autism spectrum disorder. G3 (Bethesda).
2012;2:1665–85.
9. Feng Y, Cheng D, Zhang C, Li Y, Zhang Z, Wang J, et al.
Association between ErbB4 single nucleotide polymorphisms and
susceptibility to schizophrenia: a meta-analysis of case-control
studies. Medicine. 2017;96:e5920.
10. Takahashi Y, Fukuda Y, Yoshimura J, Toyoda A, Kurppa K,
Moritoyo H, et al. ERBB4 mutations that disrupt the neuregulin-
ErbB4 pathway cause amyotrophic lateral sclerosis type 19. Am J
Hum Genet. 2013;93:900–5.
11. Firth HV, Richards SM, Bevan AP, Clayton S, Corpas M, Rajan
D, et al. DECIPHER: database of chromosomal imbalance and
phenotype in humans using ensembl resources. Am J Hum Genet.
2009;84:524–33.
12. Gassmann M, Casagranda F, Orioli D, Simon H, Lai C, Klein R,
et al. Aberrant neural and cardiac development in mice lacking the
ErbB4 neuregulin receptor. Nature. 1995;378:390–4.
13. Golub MS, Germann SL, Lloyd KCK. Behavioral characteristics
of a nervous system-specific erbB4 knock-out mouse. Behav
Brain Res. 2004;153:159–70.
14. Wang H, Liu F, Chen W, Sun X, Cui W, Dong Z, et al. Genetic
recovery of ErbB4 in adulthood partially restores brain functions
in null mice. Proc Natl Acad Sci USA. 2018;115:13105–10.
15. Bean JC, Lin TW, Sathyamurthy A, Liu F, Yin D-M, Xiong W-C,
et al. Genetic labeling reveals novel cellular targets of schizo-
phrenia susceptibility gene: distribution of GABA and Non-
GABA ErbB4-positive cells in adult mouse brain. J Neurosci.
2014;34:13549–66.
16. Mitchell RM, Janssen MJ, Karavanova I, Vullhorst D, Furth K,
Makusky A, et al. ErbB4 reduces synaptic GABAA currents
independent of its receptor tyrosine kinase activity. Proc Natl
Acad Sci USA. 2013;110:19603–8.
17. Tan G-H, Liu Y-Y, Hu X-L, Yin D-M, Mei L, Xiong Z-Q.
Neuregulin 1 represses limbic epileptogenesis through ErbB4 in
parvalbumin-expressing interneurons. Nat Neurosci.
2012;15:258–66.
18. Halvardson J, Zhao JJ, Zaghlool A, Wentzel C, Georgii-Hemming
P, Månsson E, et al. Mutations in HECW2 are associated with
intellectual disability and epilepsy. J Med Genet.
2016;53:697–704.
19. Lemke JR, Hendrickx R, Geider K, Laube B, Schwake M, Harvey
RJ, et al. GRIN2B mutations in West syndrome and intellectual
disability with focal epilepsy. Ann Neurol. 2014;75:147–54.
20. MacDonald JR, Ziman R, Yuen RKC, Feuk L, Scherer SW. The
database of genomic variants: a curated collection of structural
variation in the human genome. Nucleic Acids Res. 2014;42:
D986–92. Database issue
21. Lowther C, Speevak M, Armour CM, Goh ES, Graham GE, Li C,
et al. Molecular characterization of NRXN1 deletions from 19,263
clinical microarray cases identifies exons important for neurode-
velopmental disease expression. Genet Med. 2017;19:53–61.
22. Mucha BE, Banka S, Ajeawung NF, Molidperee S, Chen GG,
Koenig MK, et al. Correction: a new microdeletion syndrome
involving TBC1D24, ATP6V0C, and PDPK1 causes epilepsy,
microcephaly, and developmental delay. Genet Med.
2019;21:2159–60.
23. Kasher PR, Schertz KE, Thomas M, Jackson A, Annunziata S,
Ballesta-Martinez MJ, et al. Small 6q16.1 deletions encompassing
POU3F2 cause susceptibility to obesity and variable develop-
mental delay with intellectual disability. Am J Hum Genet.
2016;98:363–72.
24. Cuvertino S, Stuart HM, Chandler KE, Roberts NA, Armstrong R,
Bernardini L, et al. ACTB Loss-of-function mutations result in a
pleiotropic developmental disorder. Am J Hum Genet.
2017;101:1021–33.
ERBB4 exonic deletions on chromosome 2q34 in patients with intellectual disability or epilepsy
